USPTO Examiner HADDAD MAHER M - Art Unit 1641

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18922371METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODYOctober 2024March 2025Allow510YesNo
18815390FUSION PROTEIN COMPRISING ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOFAugust 2024May 2025Allow911YesNo
18750999PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024June 2025Abandon1201NoNo
18750887PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024June 2025Abandon1201NoNo
18750908PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCERJune 2024April 2025Abandon1010NoNo
18745750ANTI-RECEPTOR EXPRESSED ON LYMPHOID TISSUES (RELT) RECOMBINANT MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOFJune 2024November 2024Allow510YesNo
18733287Anti-DLL3 Antibodies and Uses ThereofJune 2024April 2025Allow1101YesNo
18607180ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN AND USE THEREOFMarch 2024August 2024Allow510NoNo
18588667COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASISFebruary 2024May 2025Abandon1510NoNo
18414799COMPLEMENT COMPONENT C5 ANTIBODIESJanuary 2024April 2025Abandon1510NoNo
18403218INHIBITORS OF COMPLEMENT FACTOR HJanuary 2024December 2024Allow1211YesNo
18394365TREATMENT OF CARDIOMETABOLIC DISEASE WITH INHIBITORS OF TYPE I INTERFERON SIGNALLINGDecember 2023May 2025Allow1721YesNo
18492125PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCEROctober 2023January 2025Abandon1521YesNo
18480153TNF-ALPHA IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORSOctober 2023March 2025Allow1810YesNo
18472144MONOCLONAL ANTIBODY AGAINST HUMAN LAG-3, METHOD FOR PREPARING THE SAME, AND USE THEREOFSeptember 2023April 2025Allow1911YesNo
18354934CD1a ANTIBODIES AND USES THEREOFJuly 2023June 2025Allow2211YesNo
18354611TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGANDJuly 2023April 2025Abandon2110NoNo
18349027ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOFJuly 2023April 2025Allow2211NoNo
18344711IL2RBETA/COMMON GAMMA CHAIN ANTIBODIESJune 2023June 2025Abandon2411NoNo
18341202ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERSJune 2023December 2024Allow1710YesNo
18338946ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOFJune 2023April 2025Allow2111YesNo
18333869METHODS FOR TARGETING THE IMMUNE CHECKPOINT PD1 PATHWAY FOR TREATING PULMONARY FIBROSISJune 2023February 2025Allow2011NoNo
18331623HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND USES THEREOFJune 2023March 2025Abandon2102NoNo
18321711MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOFMay 2023February 2025Abandon2110NoNo
18296265ANTI-PCSK9 ANTIBODIESApril 2023November 2024Allow2010NoNo
18193889ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2March 2023January 2025Abandon2210NoNo
18187475MONOCLONAL ANTIBODIES TO CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 (CTLA-4)March 2023October 2024Allow1920YesNo
18022113ANTIBODY SPECIFICALLY BOUND TO GLYCOSYLATED CEACAM5February 2023February 2024Allow1211YesNo
18170742ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCERFebruary 2023November 2024Abandon2101NoNo
18097078MONOCLONAL ANTIBODY AND ANTIGENS FOR DIAGNOSING AND TREATING LUNG DISEASE AND INJURYJanuary 2023January 2025Abandon2410NoNo
18153277NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPYJanuary 2023April 2024Allow1600NoNo
18153103ANTIBODIES THAT BIND INTEGRIN AVB8 AND USES THEREOFJanuary 2023September 2024Allow2011YesNo
18091145METHOD FOR DETECTING OR TREATING TRIPLE NEGATIVE BREAST CANCERDecember 2022April 2025Allow2740YesNo
18146951METHODS OF TREATMENT BY TARGETING VCAM1 AND MAEADecember 2022August 2024Allow1910NoNo
18084618ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOFDecember 2022February 2025Abandon2611NoNo
18064663COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTAGONIST OF PD-1 AND AN ANTI-CTLA4 ANTIBODYDecember 2022May 2025Abandon2921NoNo
17999444TNF-ALPHA IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORSNovember 2022August 2023Allow920YesNo
18056825COLLAGEN-LOCALIZED IMMUNOMODULATORY MOLECULES AND METHODS THEREOFNovember 2022December 2024Allow2521YesNo
17980751NOVEL PEPTIDESNovember 2022October 2023Allow1211YesNo
18050817ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERSOctober 2022April 2024Allow1810YesNo
17975865ANTI-NR10 ANTIBODY AND USE THEREOFOctober 2022July 2024Abandon2101NoNo
17995168FULLY HUMAN ANTI-HUMAN CD22 CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOFSeptember 2022June 2025Allow3300YesNo
17931386Anti-Abeta AntibodiesSeptember 2022May 2025Abandon3221NoNo
17930704ANTI-ANGPTL3 ANTIBODIES AND USES THEREOFSeptember 2022March 2025Abandon3011NoNo
17819287ANTIBODIES AGAINST OX-40 AND USES THEREOFAugust 2022October 2024Abandon2611NoNo
17869872ROR1 ANTIBODIESJuly 2022November 2024Abandon2811NoNo
17813375HUMAN ANTI-SEMAPHORIN 4D ANTIBODYJuly 2022January 2024Allow1810NoNo
17844484MATERIALS AND METHODS FOR HINGE REGIONS IN FUNCTIONAL EXOGENOUS RECEPTORSJune 2022March 2024Abandon2101NoNo
17836457Anti-IL1RAP antibodyJune 2022April 2024Allow2211YesNo
17833077ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLSJune 2022August 2024Allow2611YesNo
17767171CONNEXIN 43 ANTIBODIES AND USE THEREOFApril 2022August 2024Allow2810YesNo
17689869CD8A-Binding Fibronectin Type III DomainsMarch 2022November 2023Allow2001YesNo
17592227INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASEFebruary 2022March 2024Abandon2501NoNo
17592154METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTSFebruary 2022March 2024Abandon2501NoNo
17586662ANTI-ANGPTL3 ANTIBODIES AND USES THEREOFJanuary 2022February 2024Abandon2501NoNo
17578294ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATIONJanuary 2022March 2024Abandon2610NoNo
17571286METHODS FOR TREATING HYPERLIPIDEMIA WITH AN ANGPTL8 INHIBITOR AND AN ANGPTL3 INHIBITORJanuary 2022October 2024Abandon3311NoNo
17563502ANTI-PD-L1 ANTIBODIES AND USES THEREOFDecember 2021January 2024Abandon2501NoNo
17557898ENGINEERED ANTIBODY FOR INHIBITION OF FIBROSISDecember 2021February 2024Abandon2610NoNo
17552486USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTSDecember 2021February 2024Abandon2601NoNo
17552211USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTSDecember 2021February 2024Abandon2601NoNo
17537275METHODS FOR TREATING OR PREVENTING ATHEROSCLEROSIS BY ADMINISTERING AN INHIBITOR OF ANGPTL3November 2021April 2025Abandon4121NoNo
17532664ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING SAMENovember 2021March 2025Abandon4031NoNo
17532660ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING SAMENovember 2021December 2024Abandon3730NoNo
17454837COMBINATION THERAPIES USING ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULESNovember 2021June 2025Allow4320YesNo
17610328BINDING MOLECULESNovember 2021June 2025Abandon4310NoNo
17520480PROTEIN BINDING TO FIBRONECTIN B DOMAINNovember 2021January 2024Allow2611YesNo
17512500Methods and Compositions for Improving Antiangiogenic Therapy with Anti-IntegrinsOctober 2021February 2025Abandon3921NoNo
17511343Inhibition of Tau PropagationOctober 2021June 2024Abandon3121YesNo
17452042HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINSOctober 2021January 2024Abandon2710NoNo
17506667ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING A THROMBOTIC DISEASE OF THE RETINAOctober 2021July 2024Abandon3320YesYes
17503592ANTIBODIES TO CANINE AND FELINE ONCOSTATIN M RECEPTOR BETA AND USES THEREOFOctober 2021August 2024Allow3421NoNo
17496664ANTI-INTEGRIN BETA-1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOFOctober 2021July 2024Abandon3311YesNo
17441861MAGE A4 T CELL RECEPTORSSeptember 2021February 2025Allow4101NoNo
17439971EXPANDED NK CELL FRACTIONS FOR TRANSPLANTATION IN COMBINATION THERAPYSeptember 2021April 2025Allow4210NoNo
17474359SH3YL1 Antibodies, Compositions Comprising the Same, and Vectors and Uses ThereofSeptember 2021July 2023Allow2311YesNo
17475214USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING FIBROSISSeptember 2021April 2024Allow3121YesNo
17458019METHODS OF INHIBITING COMPLEMENT FACTOR H (CFH) COMPRISING ADMINISTERING AN ANTIBODY THAT BINDS CFHAugust 2021December 2022Allow1511YesNo
17406611COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPYAugust 2021December 2023Abandon2801NoNo
17399725ANTIBODY TO FIBROSIS-RELATED MOLECULE AND MEDICAL APPLICATION THEREOFAugust 2021August 2023Allow2410NoNo
17396517CHIMERIC ANTIGEN RECEPTORS COMPRISING BCMA-SPECIFIC FIBRONECTIN TYPE III DOMAINS AND USES THEREOFAugust 2021November 2023Abandon2710NoNo
17395372ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELSAugust 2021October 2023Abandon2601NoNo
17395365ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELSAugust 2021October 2023Abandon2601NoNo
17392740ANTI-IDIOTYPE ANTIBODIES TARGETING ANTI-CD70 CHIMERIC ANTIGEN RECEPTORAugust 2021June 2023Allow2311YesNo
17376830ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-KLK2 ANTIBODIESJuly 2021February 2024Allow3121YesNo
17369670MODULATION OF LEUKOCYTE ACTIVITY IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASEJuly 2021October 2024Abandon3921NoNo
17350763DOPPEL-TARGETING ANTIBODIESJune 2021October 2023Allow2811YesNo
17312083ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND USE THEREOFJune 2021January 2025Allow4410YesNo
17338991Antibodies to MAdCAMJune 2021June 2023Allow2510NoNo
17307709COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASISMay 2021October 2023Allow2921YesNo
17306544INHIBITING ANTI-ENPP1 ANTIBODIESMay 2021July 2023Allow2711YesNo
17239512TREATMENT WITH ANTI-ALPHA4BETA7 ANTIBODYApril 2021December 2024Allow4412YesNo
17236810HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47April 2021July 2023Allow2610YesNo
17301741ANTI-TENASCIN C ANTIBODIES AND USES THEREOFApril 2021July 2023Allow2710NoNo
17208014ANTIBODYMarch 2021October 2024Abandon4340NoNo
17194054Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress SyndromeMarch 2021February 2025Allow4731NoNo
17184116METHOD OF TREATING PRIMARY SCLEROSING CHOLANGITISFebruary 2021April 2025Allow4921YesYes
17177179FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9February 2021August 2023Allow3011NoNo
17175913ANTIBODIES AGAINST MAC-1February 2021January 2024Abandon3530YesNo
17174610Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating DisordersFebruary 2021October 2024Abandon4401NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HADDAD, MAHER M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
1
(20.0%)
Examiner Reversed
4
(80.0%)
Reversal Percentile
89.9%
Higher than average

What This Means

With a 80.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
49
Allowed After Appeal Filing
20
(40.8%)
Not Allowed After Appeal Filing
29
(59.2%)
Filing Benefit Percentile
65.6%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 40.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner HADDAD, MAHER M - Prosecution Strategy Guide

Executive Summary

Examiner HADDAD, MAHER M works in Art Unit 1641 and has examined 313 patent applications in our dataset. With an allowance rate of 78.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner HADDAD, MAHER M's allowance rate of 78.6% places them in the 39% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by HADDAD, MAHER M receive 1.90 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HADDAD, MAHER M is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +39.9% benefit to allowance rate for applications examined by HADDAD, MAHER M. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 59.0% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 89.1% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 82.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 65.1% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 10.5% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.3% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.